M-SRG
Nomenclature
SD-Rag2em1SmocIl2rgem1Smoc
Cat. NO.
NR-KO-210360
Strain State
Repository Live
Gene Summary
Gene Symbol
Model Description
Validation Data
Fig1. Complete deletion of T, B and NK cells of M-SRG rats. Spleen and peripheral blood cells from SD and M-SRG rats were collected to analyze their compositions of T, B and NK cells by FACS.
Fig2. Subcutaneous xenograft tumor growth of HT29 cells in M-SRG rats. Human colorectal adenocarcinoma cell line HT-29 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig3. Subcutaneous xenograft tumor growth of PC-3 cells in M-SRG rats. Human prostatic adenocarcinoma cell line PC-3 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig4. Subcutaneous xenograft tumor growth of LNCaP clone FGC cells in M-SRG rats. Human metastatic prostate carcinoma cell line LNCaP clone FGC (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig5. Subcutaneous xenograft tumor growth of A2780 cells in M-SRG rats. Human ovarian cancer cell line HT-29 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig6. Subcutaneous xenograft tumor growth of MV4-11 cells in M-SRG rats. Human monocytic leukemia cell line MV4-11 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig7. Subcutaneous xenograft tumor growth of OCI-AML-3 cells in M-SRG rats. Human acute myeloid leukemia cell line OCI-AML-3 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A) Tumor volume. (B) Body weight change.
Fig8. Blood Routine Tests in M-SRG rats.
Fig9. Blood biochemistry in M-SRG rats.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
